Albireo announces publication of the picture study highlighting the caregiver impact of pfic, a rare and devastating children's liver disease

Boston, feb. 14, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced the publication of the picture study in orphanet journal of rare disease . a multinational, retrospective, cross-sectional study, picture evaluated and quantified the impact that progressive familial intrahepatic cholestasis (pfic) has on caregivers and found a significant caregiver-reported burden on health-related quality of life (hrqol), impairment of daily activities, reduced sleep, impact on work productivity, career building challenges and relationship strain. the study illustrates for the first time that pfic levies a substantial burden that extends beyond the individuals with the disease to those caring for them.
ALBO Ratings Summary
ALBO Quant Ranking